Treatment of Bladder Spasticity (Toxins2002)

Subject: Treatment of Bladder Spasticity (Toxins2002)

Date: 6/27/2002

E-MOVE reports from the International Conference 2002: Basic and Therapeutic Aspects of Botulinum and Tetanus Toxins. Poster (P) and page (R) numbers are from Naunyn Schmiederberg's Archives of Pharmacology 2002;365(supplement 2).

Botulinum-A toxin detrusor injection as a novel approach in the treatment of bladder spasticity in children with neurogenic bladder
H Schulte-Baukloh, T Michael, HH Knispel
P122; R39

Bladder spasticity can be effectively treated with BTX-A, according to this study.

Twenty children with detrusor hyperreflexia who were ineffectively treated with anticholinergic drugs, and who required daily intermittent catheterization, received 85-300 units BOTOX to 40-50 sites in the detrusor. Compared to baseline, measurements at 2-4 weeks and 3 months showed these highly significant improvements:

--Maximum detrusor pressure: 60%; 50%
--Reflex volume: 220%; 130%
--Bladder capacity: 160%; 150%

The authors suggest that injections of BTX-A may be an effective additive or alternative treatment to anticholinergic drugs in this condition.

--
2002 E-MOVE conference reports are made possible in part through unrestricted educational grants from Elan Pharmaceuticals, GlaxoSmithKline, and Pharmacia Corporation.

E-MOVE Editor: Richard Robinson, NASW, WE MOVE

Related CME Activities - Valid for AMA PRA Category 1 Credits(s)™